← All trials
NCT02838992
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2017
- Primary completion
- Dec 1, 2018
- Completion date
- Jul 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Harbin Medical UniversityCollaborator
- Jinhua Central HospitalCollaborator
- Linyi People's HospitalCollaborator
- Qingdao UniversityCollaborator
- Shengjing HospitalCollaborator
- Guangzhou Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Shandong University of Traditional Chinese MedicineCollaborator
- Shandong Cord Blood BankCollaborator
- Qingdao Center Medical GroupCollaborator
- Weifang Medical UniversityCollaborator
- Tai'an Central HospitalCollaborator
- Yishui Central Hospital of LINYICollaborator
- Nanjing Medical UniversityCollaborator
- Jiangxi Provincial People's HospitalCollaborator
- Jining NO.1 People 's HospitalCollaborator
- People's Liberation Army of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.